MARKET

CDNA

CDNA

CareDx
NASDAQ

Real-time Quotes | Nasdaq Last Sale

31.39
+1.14
+3.77%
After Hours: 31.39 0 0.00% 16:00 05/22 EDT
OPEN
30.25
PREV CLOSE
30.25
HIGH
31.48
LOW
29.96
VOLUME
325.41K
TURNOVER
--
52 WEEK HIGH
41.27
52 WEEK LOW
13.04
MARKET CAP
1.37B
P/E (TTM)
-65.7382
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average CDNA stock price target is 42.20 with a high estimate of 54.00 and a low estimate of 35.00.

EPS

CDNA News

More
Edited Transcript of CDNA earnings conference call or presentation 30-Apr-20 8:30pm GMT
Q1 2020 CareDx Inc Earnings Call
Thomson Reuters StreetEvents · 5d ago
CareDx Reports Its AlloSeq Tx 17 Wins CE Mark Approval
Benzinga · 05/15 11:10
CareDx's AlloSeq Tx 17 Awarded CE Mark Approval
SOUTH SAN FRANCISCO, Calif., May 15, 2020 -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development and commercialization of.
GlobeNewswire · 05/15 11:00
CareDx and Veracyte Announce Exclusive Partnership for Transplant Rejection Testing on nCounter System
CareDx and Veracyte Announce Exclusive Partnership for Transplant Rejection Testing on nCounter System
Business Wire · 05/14 12:15
CareDx Brings the Transplant Patient Community Together
SOUTH SAN FRANCISCO, Calif., May 07, 2020 -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of.
GlobeNewswire · 05/07 11:00
CareDx Collaborates with Weill Cornell Medicine to Lead the Development and Commercialization of UroMap
GlobeNewswire · 05/05 12:00
Here's Why We're Not At All Concerned With CareDx's (NASDAQ:CDNA) Cash Burn Situation
Simply Wall St. · 05/02 13:35
HC Wainwright & Co. Reiterates Buy on CareDx, Lowers Price Target to $40
HC Wainwright & Co. reiterates CareDx (NASDAQ:CDNA) with a Buy and lowers the price target from $43 to $40.
Benzinga · 05/01 11:28

Industry

Biotechnology & Medical Research
+1.01%
Pharmaceuticals & Medical Research
+0.05%

Hot Stocks

Symbol
Price
%Change

About CDNA

CareDx, Inc. is a molecular diagnostics company. The Company is focused on the discovery, development and commercialization of clinically differentiated diagnostic surveillance solutions for transplant patients. The Company's commercialized testing solution, the AlloMap heart transplant molecular test (AlloMap), is a gene expression test that helps clinicians monitor and identify heart transplant recipients with stable graft function having a low probability of moderate/severe acute cellular rejection. Its products under development for transplant monitoring include AlloSure, a development-stage transplant surveillance solution, which applies next generation sequencing to detect and quantitate genetic differences between donor-derived cell-free deoxyribonucleic acid (dd-cfDNA) in the blood stream emanating from the donor heart. It offers the AlloMap Score Variability service, which provides complementary information to help personalize long-term care of heart transplant recipients.
More

Webull offers kinds of CareDx Inc stock information, including NASDAQ:CDNA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CDNA stock news, and many more online research tools to help you make informed decisions.